Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis

A Steinmaurer
, I Wimmer
, T Berger
, PS Rommer
, J Sellner

Department of Neurology

Research output: Contribution to journal › Review article › peer-review

17 Citations (Web of Science)

Original language	English
Pages (from-to)	437-444
Journal	CURRENT PHARMACEUTICAL DESIGN
Volume	28
Issue number	6
DOIs	https://doi.org/10.2174/1381612827666210701152934
Publication status	Published - 2022

Keywords

X-LINKED AGAMMAGLOBULINEMIA
CHRONIC LYMPHOCYTIC-LEUKEMIA
B-CELL DIFFERENTIATION
FACTOR-KAPPA-B
SRC FAMILY
ACTIVATION
BTK
EXPRESSION
GENE
AUTOIMMUNITY

Access to Document

10.2174/1381612827666210701152934

Cite this

Steinmaurer, A., Wimmer, I., Berger, T., Rommer, PS., & Sellner, J. (2022). Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. CURRENT PHARMACEUTICAL DESIGN , 28(6), 437-444. https://doi.org/10.2174/1381612827666210701152934

Steinmaurer, A ; Wimmer, I ; Berger, T et al. / Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. In: CURRENT PHARMACEUTICAL DESIGN 2022 ; Vol. 28, No. 6. pp. 437-444.

@article{a361e83340514c4ab2150eb98e0548ce,

title = "Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis",

keywords = "X-LINKED AGAMMAGLOBULINEMIA, CHRONIC LYMPHOCYTIC-LEUKEMIA, B-CELL DIFFERENTIATION, FACTOR-KAPPA-B, SRC FAMILY, ACTIVATION, BTK, EXPRESSION, GENE, AUTOIMMUNITY",

author = "A Steinmaurer and I Wimmer and T Berger and PS Rommer and J Sellner",

note = "Sellner: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria",

year = "2022",

doi = "10.2174/1381612827666210701152934",

language = "English",

volume = "28",

pages = "437--444",

journal = "CURRENT PHARMACEUTICAL DESIGN ",

issn = "1381-6128",

number = "6",

}

Steinmaurer, A, Wimmer, I, Berger, T, Rommer, PS & Sellner, J 2022, 'Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis', CURRENT PHARMACEUTICAL DESIGN , vol. 28, no. 6, pp. 437-444. https://doi.org/10.2174/1381612827666210701152934

Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. / Steinmaurer, A; Wimmer, I; Berger, T et al.
In: CURRENT PHARMACEUTICAL DESIGN , Vol. 28, No. 6, 2022, p. 437-444.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis

AU - Steinmaurer, A

AU - Wimmer, I

AU - Berger, T

AU - Rommer, PS

AU - Sellner, J

N1 - Sellner: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria

PY - 2022

Y1 - 2022

KW - X-LINKED AGAMMAGLOBULINEMIA

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - B-CELL DIFFERENTIATION

KW - FACTOR-KAPPA-B

KW - SRC FAMILY

KW - ACTIVATION

KW - BTK

KW - EXPRESSION

KW - GENE

KW - AUTOIMMUNITY

U2 - 10.2174/1381612827666210701152934

DO - 10.2174/1381612827666210701152934

M3 - Review article

C2 - 34218776

SN - 1381-6128

VL - 28

SP - 437

EP - 444

JO - CURRENT PHARMACEUTICAL DESIGN

JF - CURRENT PHARMACEUTICAL DESIGN

IS - 6

ER -

Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J. Brutonxxxs Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. CURRENT PHARMACEUTICAL DESIGN . 2022;28(6):437-444. doi: 10.2174/1381612827666210701152934